Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (144)	4/13/1999 3:28:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1834

Rich? Who is Rich? ************* US5882926: Excitatory amino acid transporter gene and uses Inventor(s): Amara; Susan G. , Portland, OR Arriza; Jeffrey L. , Kennett Square, PA Eliasof; Scott , Portland, OR Kavanaugh; Michael P. , Portland, OR Applicant(s): Oregon Health Sciences University, Portland, OR Issued/Filed Dates: March 16, 1999 / Oct. 10, 1997 Application Number: US1997000948569 Abstract: This invention relates to novel mammalian excitatory amino acid transporter proteins and genes encoding such proteins. The invention is directed towards the isolation, characterization and use of human excitatory amino acid transporter proteins for pharmacological screening of analogues, agonists, antagonists, inhibitors, modulators and facilitators of excitatory amino acid transport in a variety of tissues, particularly neuronal tissues. This invention provides isolated nucleic acid encoding a novel excitatory amino acid transporter subtype that is specifically expressed in retina. Also provided are recombinant expression constructs capable of expressing this novel transporter in transformed prokaryotic and eukaryotic cells, and also provides such transformed cell cultures producing the novel human transporter. Purified transporter protein and membranes comprising the transporter protein are also provided. The invention provides methods of screening compounds in vitro for transporter binding properties using said preparations of protein and membranes from transformed cell cultures, as well as from amphibian oocytes expressing the human transporter protein provided herein. ********************** NBIX should receive at least three years of funding for this project from AHP. I like the CRF antagonist project. I like the collaboration with Rigel, and the focus on inflammation/gliosis and Alzheimer's (should be no surprise, given my interest in GLIA). Gary Lyons is a class-act manager. I know him casually (he wouldn't recognize me) from Genentech. Open market purchase of shares late last year at $6.50. The APL programs are, IMO, longshots. The diabetes program is theirs alone (please check that, as I may be wrong). I assign zero value for these programs, but Steinman is an asset and the upside would be huge. A GABA(A) Receptor Agonist, for insomnia. As one can also tell from my interest in GLIA, I want to be heavily invested in sleep disorders. IGF-1, melanocortin receptors, IL-4 fusion toxin, etc..... this company is trying to flesh out a pipeline and to get cash flowing through the labs to minimize burn. Neuro subsector strongly depressed. Aging population dictates, to me, that this is irrational. Tons of cash, allowing for independence and leverage with respect to potential collaborations. Price:book of 1.2 Cheers! Rick